Skip to main content

Table 1 General characteristics of patients who evaluated devices using the Global Usability Score questionnaire

From: Patients’ usability of seven most used dry-powder inhalers in COPD

 

Instructed to DPI (n = 74)

Not instructed to DPI (n = 29)

Group 1

Group 2

Group 3

p

Group 1

Group 2

Group 3

p

N

27

28

19

 

9

9

11

 

Mean age (SD)

68.6 (12.3)

69 (10.4)

67.6 (12.4)

0.9234

58.9 (9.0)

64.3 (13.4)

64.9 (11.2)

0.4578

Sex (male)

62.5%

64.3%

57.9%

0.9046

22.2%

33.3%

45.5%

0.5515

Countrya

   

0.0002

   

0.9999

 North

92.3%

39.3%

63.2%

 

66.7%

66.7%

63.6%

 

 Center

3.8%

17.9%

10.5%

 

33.3%

33.3%

27.3%

 

 South and Islands

3.8%

42.9%

26.35

 

0.0%

0.0%

9.1%

 

Educationa

   

0.1658

   

0.5683

 Primary

13.0%

7.7%

10.5%

 

0.0%

11.1%

0.0

 

 Lower secondary

26.1%

57.7%

42,1%

 

44.4%

66.7%

57.9%

 

 Upper secondary

56.5%

30.8%

42,1%

 

44.4%

22.2%

31.6%

 

 Degree

4.3%

3.8%

5,3%

 

11.1%

0.0%

10.5%

 
  1. Group1 tested Breezhaler, Spiromax, Nexthaler, and Ellipta; Group 2 tested Breezhaler, Spiromax, Diskus, and Turbohaler; Group 3 tested Breezhaler and Genuair; DPI dry powder inhalers, SD standard deviation
  2. a Information about country and education are reported also for Group 3, even though available only a few patients who answered those questions